文献速递类风湿关节炎

四种JAK抑制剂治疗类风湿关节炎的2年真实世界疗效比较

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.
PubMed 文献 · RMD Open · 2026-01-16

基于FIRST多中心登记库的回顾性队列研究,纳入607例JAK抑制剂治疗疗程(托法替布159、巴瑞替尼262、乌帕替尼122、非戈替尼64),比较2年临床疗效。多变量分析显示四种JAK抑制剂在CDAI变化和患者报告结局上无显著差异,但乌帕替尼组在压痛关节数和评估者总体评估两项CDAI组分上改善更明显;2年总体药物留存率为78%。

要点

  • 四种JAK抑制剂2年CDAI变化及患者报告结局无显著差异
  • 乌帕替尼组压痛关节数和评估者总体评估改善更明显
  • 2年总体留存率78%,因疗效不足停药率6.5/100人年

核心结论

  • 真实世界中四种JAK抑制剂2年疗效无临床意义差异,但研究不足以检测安全性差异。

研究设计与样本

  • 回顾性队列研究,使用FIRST多中心类风湿关节炎患者登记库数据,共纳入607个JAK抑制剂治疗疗程。

主要发现

  • 2年总体留存率为78%,因疗效不足停药率为6.5/100人年,因不良事件停药率为4.2/100人年。
  • 按实际观察分析,乌帕替尼和非戈替尼组改善较慢,但多变量分析显示CDAI和患者报告结局无显著差异。
  • 乌帕替尼组在压痛关节数和评估者总体评估两项CDAI组分上改善更明显。

临床怎么用

  • 四种JAK抑制剂均可用于类风湿关节炎的2年治疗,疗效差异不显著,选择时需结合患者特征和安全性考量。

局限性

  • 研究不足以检测四种JAK抑制剂在安全性方面的差异。
  • 基线特征在各治疗组间存在明显差异,乌帕替尼和非戈替尼多作为老年合并症患者的二线JAK抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the 2-year clinical effectiveness of the four globally approved Janus kinase inhibitors (JAKis; tofacitinib (TOF), baricitinib (BAR), upadacitinib (UPA) and filgotinib (FIL)) in patients with rheumatoid arthritis (RA) in real-world settings. METHODS: This retrospective cohort study used data from FIRST registry, a multicentre registry of patients with RA. The primary endpoint was the change in Clinical Disease Activity Index (CDAI) score at year 2. Secondary endpoints included changes in individual CDAI components, patient-reported outcomes (PROs) and reasons for JAKi discontinuation. Multivariable mixed-effects models adjusted for baseline characteristics were used to compare the four JAKis. RESULTS: A total of 607 treatment courses with JAKis (TOF: 159, BAR: 262, UPA: 122, FIL: 64) were included. Baseline characteristics differed notably among treatment groups: UPA and FIL were frequently used as the second-line JAKis for older patients with comorbidities. The 2-year overall retention rate was 78%. The most common reason for discontinuation was insufficient effectiveness, with 6.5/100 person-years (py), followed by adverse events of 4.2/100 py. As-observed analysis demonstrated the slower improvement in the UPA and FIL groups. However, multivariable analysis revealed no significant differences in CDAI or PROs. The UPA group demonstrated greater improvement in two CDAI components: tender joint count and evaluator's global assessment. CONCLUSION: This real-world study found no clinically meaningful differences in 2-year effectiveness among four JAKis, although the study was not powerful enough to detect differences in safety. Further long-term, real-world data are needed to evaluate the safety of these agents and refine their risk-benefit profiles.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sonomoto K, Nakayamada S, Sakai H, et al. Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry. RMD Open. 2026. PMID: 41545310. doi:10.1136/rmdopen-2025-006503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。